Clinical Trials
8 trialsNCT06924606 2026-02-06
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Recruiting
NCT04043195 2025-05-28
NSCLC
University of California, San Diego
Phase 1/2 Active not recruiting
NCT03127449 2025-04-03
AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Allist Pharmaceuticals, Inc.
Phase NA Terminated
NCT06751849 2024-12-30
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
The First Affiliated Hospital of Nanchang University
Phase 2 Recruiting
NCT06751901 2024-12-30
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment
The First Affiliated Hospital of Nanchang University
Phase 2 Recruiting
NCT06752044 2024-12-30
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
The First Affiliated Hospital of Nanchang University
Phase NA Recruiting
NCT06752057 2024-12-30
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
The First Affiliated Hospital of Nanchang University
Phase NA Recruiting
NCT05106335 2023-08-16
A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Terminated